Media headlines about iCAD (NASDAQ:ICAD) have trended somewhat positive on Saturday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. iCAD earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the technology company an impact score of 45.6270309932993 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, ValuEngine upgraded iCAD from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd.
ICAD stock traded up $0.04 during trading on Friday, hitting $3.20. The company had a trading volume of 26,753 shares, compared to its average volume of 24,035. iCAD has a one year low of $2.93 and a one year high of $4.89. The stock has a market capitalization of $52.65 million, a PE ratio of -5.25 and a beta of 1.32. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.50 and a quick ratio of 1.33.
iCAD (NASDAQ:ICAD) last announced its earnings results on Monday, May 14th. The technology company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.07). iCAD had a negative net margin of 61.83% and a negative return on equity of 59.65%. The company had revenue of $6.31 million during the quarter, compared to the consensus estimate of $6.97 million. research analysts expect that iCAD will post -0.51 earnings per share for the current year.
iCAD Company Profile
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.